{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:21:54Z","timestamp":1790655714282,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["30711"],"award-info":[{"award-number":["30711"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02361134"],"award-info":[{"award-number":["GR-2016-02361134"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP B33C22001030006"],"award-info":[{"award-number":["CUP B33C22001030006"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministry of Education and Merit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ctrv.2026.103123","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:40:14Z","timestamp":1774021214000},"page":"103123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities"],"prefix":"10.1016","volume":"145","author":[{"given":"Enza","family":"Scarlato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Dusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-7585","authenticated-orcid":false,"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctrv.2026.103123_b0005","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103123_b0015","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"Kleeff","year":"2016","journal-title":"Pancreatic cancer Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103123_b0025","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103123_b0030","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103123_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106043","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial","volume":"11","author":"Macarulla","year":"2026","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103123_b0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14796694.2025.2458458","article-title":"A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)","volume":"21","author":"Wainberg","year":"2025","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103123_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105534","article-title":"Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial","volume":"10","author":"Melisi","year":"2025","journal-title":"ESMO Open"},{"issue":"10409","key":"10.1016\/j.ctrv.2026.103123_b0050","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"100179","key":"10.1016\/j.ctrv.2026.103123_b0055","first-page":"20","article-title":"Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma","volume":"8","author":"Scarlato","year":"2025","journal-title":"ESMO gastrointestinal oncology"},{"issue":"7540","key":"10.1016\/j.ctrv.2026.103123_b0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"7592","key":"10.1016\/j.ctrv.2026.103123_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103123_b0070","doi-asserted-by":"crossref","unstructured":"Moore, Amanda R et al. \u201cRAS-targeted therapies: is the undruggable drugged?\u201d. Nature reviews. Drug discovery, vol. 19,8 (2020): 533\u2013552. doi:10.1038\/s41573-020-0068-6.","DOI":"10.1038\/s41573-020-0068-6"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103123_b0080","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0090","doi-asserted-by":"crossref","first-page":"12287","DOI":"10.1021\/acs.jmedchem.5c01441","article-title":"RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a phase III Clinical Candidate Daraxonrasib (RMC-6236)","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103123_b0100","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103123_b0110","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65035-3","article-title":"Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity","volume":"156","author":"Wilentz","year":"2000","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103123_b0115","first-page":"1501","article-title":"Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+","volume":"152","author":"Goggins","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2026.103123_b0120","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241265213","article-title":"A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?","volume":"16","author":"de Jesus","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103123_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1551038","article-title":"Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor","volume":"15","author":"Ohtsubo","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00423-024-03506-6","article-title":"Histological variants of pancreatic ductal adenocarcinoma: a survival analysis","volume":"409","author":"Bengtsson","year":"2024","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0140","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/MPA.0000000000002227","article-title":"Survival and Prognostic Factors in patients with Pancreatic Colloid Carcinoma Compared with Pancreatic Ductal Adenocarcinoma","volume":"52","author":"Khalil","year":"2023","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0145","article-title":"Colloid Carcinoma of the Pancreas with a Series of Radiological and Pathological Studies for Diagnosis: a Case Report","volume":"12","author":"Chen","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103123_b0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.32074\/1591-951X-167","article-title":"Malignant epithelial\/exocrine tumors of the pancreas","volume":"112","author":"Luchini","year":"2020","journal-title":"Pathologica"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000370111","article-title":"Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus","volume":"90","author":"Tanaka","year":"2014","journal-title":"Digestion"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103123_b0160","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early Detection of Pancreatic Cancer: Opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/j.gastro.2017.11.009","article-title":"Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas","volume":"154","author":"Lupinacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2026.103123_b0170","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1038\/modpathol.3800686","article-title":"Nonductal neoplasms of the pancreas","volume":"20","author":"Klimstra","year":"2007","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.radcr.2019.10.009","article-title":"Pancreatic acinar cell carcinoma\u2013literature review and case report of a 56-year-old man presenting with abdominal pain","volume":"15","author":"Fontenot","year":"2020","journal-title":"Radiol Case Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0180","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-14-0617","article-title":"Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","volume":"4","author":"Chmielecki","year":"2014","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103123_b0185","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","article-title":"Fusion genes in pancreatic tumors","volume":"10","author":"Gkountakos","year":"2024","journal-title":"Trends Cancer"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103123_b0190","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1200\/JCO.23.00561","article-title":"Genomic Profiling reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma","volume":"41","author":"Mandelker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103123_b0195","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/MPA.0000000000002150","article-title":"Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-based Chemotherapy in a Family with a Germline BRCA2 Variant","volume":"51","author":"Sunami","year":"2022","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103123_b0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10689-024-00390-3","article-title":"The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review","volume":"23","author":"Matsubayashi","year":"2024","journal-title":"Fam Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103123_b0205","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: challenges and Recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0210","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/cr.2007.115","article-title":"Mechanisms and functions of DNA mismatch repair","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)81333-1","article-title":"Lessons from hereditary colorectal cancer","volume":"87","author":"Kinzler","year":"1996","journal-title":"Cell"},{"issue":"48","key":"10.1016\/j.ctrv.2026.103123_b0225","doi-asserted-by":"crossref","first-page":"39752","DOI":"10.1074\/jbc.M509701200","article-title":"Human mismatch repair: reconstitution of a nick-directed bidirectional reaction","volume":"280","author":"Constantin","year":"2005","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103123_b0230","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103123_b0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2022.06.009","article-title":"Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications","volume":"132","author":"Luchini","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103123_b0240","article-title":"Tumor Mutational Burden in Real-World patients with Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103123_b0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00432-024-05841-z","article-title":"Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma","volume":"150","author":"Merz","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103123_b0255","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous Recombination Deficiency: Concepts, Definitions, and Assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103123_b0260","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0265","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103123_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00152","article-title":"Retrospective Survival Analysis of patients with Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations","volume":"2","author":"Reiss","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103123_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00115","article-title":"Outcomes in patients with Pancreatic Adenocarcinoma with Genetic Mutations in DNA damage Response Pathways: results from the know your Tumor Program","volume":"3","author":"Pishvaian","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00535-024-02173-0","article-title":"Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database","volume":"60","author":"Ishigaki","year":"2025","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103123_b0285","article-title":"Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precis","volume":"5","author":"Fusco","year":"2021","journal-title":"Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0290","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular Characterization of KRAS Wild-type Tumors in patients with Pancreatic Adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0295","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0300","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103123_b0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28171","article-title":"Patterns in Cancer Incidence among People Younger than 50 Years in the US, 2010 to 2019","volume":"6","author":"Koh","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-025-00820-0","article-title":"The burden and temporal trend of early onset pancreatic cancer based on the GBD 2021","volume":"9","author":"Tan","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0315","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1038\/s41467-022-33718-7","article-title":"Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma","volume":"13","author":"Topham","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103123_b0320","article-title":"Multiomic Characterization reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer","volume":"7","author":"Ogobuiro","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0325","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103123_b0330","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103123_b0335","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in patients with NTRK Fusion-positive Solid Tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103123_b0340","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103123_b0345","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244271","article-title":"Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor","volume":"14","author":"Poon","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103123_b0350","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.6004\/jnccn.2022.7039","article-title":"Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","volume":"20","author":"Ng","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103123_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.976450","article-title":"Efficacy of dabrafenib\/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: a case report","volume":"12","author":"Shin","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0360","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4103\/jcrt.JCRT_729_18","article-title":"Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): a case report and literature review","volume":"16","author":"Patel","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0365","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0370","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.annonc.2022.08.089","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"33","author":"Bayle","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103123_b0375","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","article-title":"Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements across Cancer Types","volume":"30","author":"Kasi","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103123_b0380","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1634\/theoncologist.2011-0127","article-title":"Molecular alterations between the primary breast cancer and the subsequent locoregional\/metastatic tumor","volume":"17","author":"Macfarlane","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103123_b0385","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1080\/15384047.2015.1113356","article-title":"Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites","volume":"16","author":"El-Deiry","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103123_b0390","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41416-019-0507-5","article-title":"Multi-omic molecular comparison of primary versus metastatic pancreatic tumours","volume":"121","author":"Brar","year":"2019","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2026.103123_b0395","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1200\/JCO.2025.43.4_suppl.758","article-title":"Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors","volume":"43","author":"McIntyre, C.A.a.R.V.a.R.A.L.a.P.W.a.J.W.R.a.D.M.a.O.R.E.M.","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103123_b0400","author":"National Comprehensive Cancer Network (NCCN)."},{"key":"10.1016\/j.ctrv.2026.103123_b0405","article-title":"Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma with a Novel ALK-KANK4 Gene Fusion","volume":"6","author":"Gaule","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103123_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.724815","article-title":"ALK Rearrangement-positive Pancreatic Cancer with Brain Metastasis has Remarkable Response to ALK Inhibitors: a Case Report","volume":"11","author":"Ou","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103123_b0415","article-title":"Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. JCO Precis","volume":"4","author":"Gower","year":"2020","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103123_b0420","doi-asserted-by":"crossref","first-page":"555","DOI":"10.6004\/jnccn.2017.0058","article-title":"Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma","volume":"15","author":"Singhi","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103123_b0425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.6004\/jnccn.2020.7641","article-title":"Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: a Case Report and Review of the Literature","volume":"19","author":"Gupta","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103123_b0430","article-title":"Durable Response with Sequential Tyrosine Kinase Inhibitor Treatment in a Patient with ROS1 Fusion-positive Pancreatic Adenocarcinoma: a Case Report","volume":"7","author":"Reutter","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:19:43Z","timestamp":1779232783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722600037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":86,"alternative-id":["S030573722600037X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103123","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103123"}}